Posted by Michael Wonder on 26 Mar 2020
Price negotiations begin for breast cancer combo drugs
25 March 2020 - Drug makers and the government will start talks this week to negotiate prices of breast cancer medicines that combined cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor with fulvestrant.
Pfizer has the first developed CDK4/6 inhibitor Ibrance (palbociclib) and Lilly, Verzenio (abemaciclib), which recently passed the regulatory review for reimbursement after winning approval in May.
The two companies will have price negotiations with the National Health Insurance Service for 60 days.
